Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

DexCom, Inc. - Common Stock (NQ: DXCM )

80.24 +0.70 (+0.88%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DexCom, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
31 32 Next >
Why Alphabet Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Intel Reports Weak Sales, Joins Boyd Gaming, Atlassian And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
DexCom (DXCM) Q1 2024 Earnings Call Transcript
DXCM earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
DXCM Stock Earnings: DexCom Beats EPS, Beats Revenue for Q1 2024
DXCM stock results show that DexCom beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Peering Into DexCom's Recent Short Interest
Via Benzinga
Dexcom Beats First-Quarter Views And Raises Sales Outlook, But Shares Crumble
The company raised the lower bound of its sales guidance for the year. 
Via Investor's Business Daily
$1000 Invested In DexCom 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Why NASDAQ:DXCM Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Dexcom Reports First Quarter 2024 Financial Results
From DexCom, Inc.
Via Business Wire
Staar Surgical Stock Climbs The Leadership Ladder With Jump To 84 RS Rating
On Thursday, implantable lens maker Staar Surgical stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier. 
Via Investor's Business Daily
3 Innovative Stocks to Buy Before Earnings Amid the Market Pullback
Today’s episode of Full Court Finance at Zacks dives into the recent stock market pullback. We then turn our attention to three innovators in their respective industries—Vertiv, Align Technology, and... 
Via Talk Markets
How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher
ResMed stock reversed higher Thursday after an analyst suggested weight-loss drugs could drive CPAP use. 
Via Investor's Business Daily
The Analyst Verdict: DexCom In The Eyes Of 4 Experts
Via Benzinga
DexCom Inc Chart Analysis
Technical analysis of the stock chart for DXCM. 
Via Talk Markets
3 Weight-Loss ETFs to Profit From the Obesity Drug Boom
Leverage Oprah's shift to prescription weight solutions with Weight-Loss ETFs, targeting companies leading in obesity treatment. 
Via InvestorPlace
Topics ETFs
Disruptive Forces: 3 Game-changing Stocks Reshaping the Tech Landscape
This April, discover three game-changing tech stocks with disruptive technologies poised to future-proof your portfolio in 2024. 
Via InvestorPlace
Why Wall Street Got Even More Excited About The Glucose Monitor — And How Dexcom, Abbott Labs Stand To Benefit
Continuous glucose monitors have spiked in popularity since the advent of weight-loss drugs. Is chronic disease at its end? 
Via Investor's Business Daily
Nasdaq Nightmares: 3 Stocks to Sell Before Reality Sets In
DoorDash, DexCom, and Advanced Micro Devices are three Nasdaq stocks to sell before reality sets in as exuberance may be fading. 
Via InvestorPlace
3 Obesity Drug Stocks Set to Skyrocket as Demand Goes Wild
Discover top obesity drug stocks set to soar as demand surges. Eli Lilly, Novo Nordisk, & Dexcom lead with revolutionary treatments 
Via InvestorPlace
DexCom Stock Sees IBD Stock Market Rating Sweetens Ups; Earns 83 RS Rating
The Relative Strength (RS) Rating for DexCom stock entered a new percentile Monday, with a rise from 80 to 83. 
Via Investor's Business Daily
2 Growth Stocks to Buy Hand Over Fist in April
These healthcare companies' target markets substantially overlap. 
Via The Motley Fool
7 Nasdaq Stocks to Sell in April Before They Crash & Burn
The momentum in growth companies is likely to run out. Move on from these Nasdaq stocks to sell in April before it's too late. 
Via InvestorPlace
Dexcom Publishes Annual Sustainability Report
From DexCom, Inc.
Via Business Wire
Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time
From DexCom, Inc.
Via Business Wire
DexCom Stock Gains from GLP-1 Diabetic Users
DexCom Inc. (NASDAQ: DXCM) is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People 
Via MarketBeat
3 Overvalued S&P 500 Stocks for Your ‘Do NOT Buy’ List
The S&P 500’s current P/E ratio is 30% higher than a year ago, making it easier to find overvalued S&P 500 stocks to buy. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Micron, Dropbox And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed lower by around 0.1% on Thursday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Market Cap Game Show: Andy Cross vs. Bill Mann
Join the "Rule Breaker Investing" fun. 
Via The Motley Fool
Dexcom Stock Shows Market Leadership, Gets Rating Upgrade. Prognosis Good.
Among its other key ratings Dexcom has a near-best 98 Earnings Per Share Rating out of 99, reflecting strong profit growth this past year. 
Via Investor's Business Daily
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.